

**Dr Selina Namchee Lo, Independent Specialist (28/12/2007)**

---

Thank you for the opportunity to provide some quick comments on this very important draft.

1) Under General 6 iii *give particular attention to needs of children.*

This could ideally be better elaborated in respects to pharmaceutical/diagnostic products and children particularly as many of the problems with access are already widely known and being worked on by WHO, IFPMA etc. For example: drug formulations researched and manufactured and registered for market to children, storage issues in hot/cold climates, responsibility of companies if marketing of new products to fund training of use and storage etc.

2) Under para 47 i *assess impact ...for disadvantaged communities* and para 48.

It is difficult to be independent M and A if the company has to establish it itself. In general very little objective analysis has been done looking at current plethora of specific philanthropic programs (or funding) of pharma and both their real impact in terms of measurable outcomes and contradictory barriers in terms of intellectual property and pricing tiers,

I wish you well in your endeavour. Please note that these current comments are independent and do not reflect the position of my work affiliation.